CQS Cayman’s Repros Therapeutics Inc. RPRX Stock Holding History

CQS Cayman’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-90,000	Closed	-$109K	–	159
2015 Q4	$109K	Sell	90,000 -150,000	-63%	-$481K	0.01%	137
2015 Q3	$1.78M	Hold	240,000	–	–	0.15%	93
2015 Q2	$1.72M	Sell	240,000 -460,000	-66%	-$3.58M	0.1%	117
2015 Q1	$6.01M	Hold	700,000	–	–	0.28%	73
2014 Q4	$6.98M	Buy	700,000 +150,000	+27%	+$1.28M	0.46%	55
2014 Q3	$5.45M	Buy	+550,000	New	+$8.14M	0.32%	78

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CQS Cayman's RPRX Position: Q1 2016 in Review

CQS Cayman sold out of Repros Therapeutics Inc. (RPRX) in Q1 2016, closing a stake of 90,000 shares — an estimated $109K sold.

CQS Cayman first reported a position in RPRX in Q3 2014 and held it in 6 quarters. The position peaked at $6.98M in Q4 2014. 53 funds tracked by Wall St. Rank hold RPRX as of Q1 2016.

CQS Cayman reported no remaining Repros Therapeutics Inc. position as of Q1 2016 after selling out during the quarter.
CQS Cayman sold 90,000 Repros Therapeutics Inc. shares in Q1 2016, an estimated $109K.
CQS Cayman first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 6 quarters.
CQS Cayman's Repros Therapeutics Inc. position peaked at $6.98M in Q4 2014.
53 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2016.

Based on CQS Cayman's 13F filing for Q1 2016, filed 4 May 2016.